465 related articles for article (PubMed ID: 15771436)
1. Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.
Campiani G; Fattorusso C; Butini S; Gaeta A; Agnusdei M; Gemma S; Persico M; Catalanotti B; Savini L; Nacci V; Novellino E; Holloway HW; Greig NH; Belinskaya T; Fedorko JM; Saxena A
J Med Chem; 2005 Mar; 48(6):1919-29. PubMed ID: 15771436
[TBL] [Abstract][Full Text] [Related]
2. Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors.
Savini L; Gaeta A; Fattorusso C; Catalanotti B; Campiani G; Chiasserini L; Pellerano C; Novellino E; McKissic D; Saxena A
J Med Chem; 2003 Jan; 46(1):1-4. PubMed ID: 12502352
[TBL] [Abstract][Full Text] [Related]
3. Further studies on the interaction of the 5-hydroxytryptamine3 (5-HT3) receptor with arylpiperazine ligands. development of a new 5-HT3 receptor ligand showing potent acetylcholinesterase inhibitory properties.
Cappelli A; Gallelli A; Manini M; Anzini M; Mennuni L; Makovec F; Menziani MC; Alcaro S; Ortuso F; Vomero S
J Med Chem; 2005 May; 48(10):3564-75. PubMed ID: 15887964
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships for inhibition of human cholinesterases by alkyl amide phenothiazine derivatives.
Darvesh S; McDonald RS; Penwell A; Conrad S; Darvesh KV; Mataija D; Gomez G; Caines A; Walsh R; Martin E
Bioorg Med Chem; 2005 Jan; 13(1):211-22. PubMed ID: 15582466
[TBL] [Abstract][Full Text] [Related]
5. Chimeric human cholinesterase. Identification of interaction sites responsible for recognition of acetyl- or butyrylcholinesterase-specific ligands.
Loewenstein Y; Gnatt A; Neville LF; Soreq H
J Mol Biol; 1993 Nov; 234(2):289-96. PubMed ID: 8230213
[TBL] [Abstract][Full Text] [Related]
6. Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.
Butini S; Campiani G; Borriello M; Gemma S; Panico A; Persico M; Catalanotti B; Ros S; Brindisi M; Agnusdei M; Fiorini I; Nacci V; Novellino E; Belinskaya T; Saxena A; Fattorusso C
J Med Chem; 2008 Jun; 51(11):3154-70. PubMed ID: 18479118
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and evaluation of isaindigotone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors.
Pan L; Tan JH; Hou JQ; Huang SL; Gu LQ; Huang ZS
Bioorg Med Chem Lett; 2008 Jul; 18(13):3790-3. PubMed ID: 18524585
[TBL] [Abstract][Full Text] [Related]
8. Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
Camps P; Formosa X; Galdeano C; Gómez T; Muñoz-Torrero D; Scarpellini M; Viayna E; Badia A; Clos MV; Camins A; Pallàs M; Bartolini M; Mancini F; Andrisano V; Estelrich J; Lizondo M; Bidon-Chanal A; Luque FJ
J Med Chem; 2008 Jun; 51(12):3588-98. PubMed ID: 18517184
[TBL] [Abstract][Full Text] [Related]
9. 4-Aryl-4-oxo-N-phenyl-2-aminylbutyramides as acetyl- and butyrylcholinesterase inhibitors. Preparation, anticholinesterase activity, docking study, and 3D structure-activity relationship based on molecular interaction fields.
Vitorović-Todorović MD; Juranić IO; Mandić LM; Drakulić BJ
Bioorg Med Chem; 2010 Feb; 18(3):1181-93. PubMed ID: 20061157
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, biological activity, and docking studies of new acetylcholinesterase inhibitors of the bispyridinium type.
Kapková P; Stiefl N; Sürig U; Engels B; Baumann K; Holzgrabe U
Arch Pharm (Weinheim); 2003 Nov; 336(11):523-40. PubMed ID: 14639745
[TBL] [Abstract][Full Text] [Related]
11. Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors.
Carolan CG; Dillon GP; Gaynor JM; Reidy S; Ryder SA; Khan D; Marquez JF; Gilmer JF
J Med Chem; 2008 Oct; 51(20):6400-9. PubMed ID: 18817366
[TBL] [Abstract][Full Text] [Related]
12. Tacrine based human cholinesterase inhibitors: synthesis of peptidic-tethered derivatives and their effect on potency and selectivity.
Butini S; Guarino E; Campiani G; Brindisi M; Coccone SS; Fiorini I; Novellino E; Belinskaya T; Saxena A; Gemma S
Bioorg Med Chem Lett; 2008 Oct; 18(19):5213-6. PubMed ID: 18786825
[TBL] [Abstract][Full Text] [Related]
13. Isosorbide-2-benzyl carbamate-5-salicylate, a peripheral anionic site binding subnanomolar selective butyrylcholinesterase inhibitor.
Carolan CG; Dillon GP; Khan D; Ryder SA; Gaynor JM; Reidy S; Marquez JF; Jones M; Holland V; Gilmer JF
J Med Chem; 2010 Feb; 53(3):1190-9. PubMed ID: 20067290
[TBL] [Abstract][Full Text] [Related]
14. Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase.
Saxena A; Redman AM; Jiang X; Lockridge O; Doctor BP
Biochemistry; 1997 Dec; 36(48):14642-51. PubMed ID: 9398183
[TBL] [Abstract][Full Text] [Related]
15. Discovery of huperzine A-tacrine hybrids as potent inhibitors of human cholinesterases targeting their midgorge recognition sites.
Gemma S; Gabellieri E; Huleatt P; Fattorusso C; Borriello M; Catalanotti B; Butini S; De Angelis M; Novellino E; Nacci V; Belinskaya T; Saxena A; Campiani G
J Med Chem; 2006 Jun; 49(11):3421-5. PubMed ID: 16722663
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, biological evaluation and molecular modeling of substituted 2-aminobenzimidazoles as novel inhibitors of acetylcholinesterase and butyrylcholinesterase.
Zhu J; Wu CF; Li X; Wu GS; Xie S; Hu QN; Deng Z; Zhu MX; Luo HR; Hong X
Bioorg Med Chem; 2013 Jul; 21(14):4218-24. PubMed ID: 23719283
[TBL] [Abstract][Full Text] [Related]
17. Overlapping drug interaction sites of human butyrylcholinesterase dissected by site-directed mutagenesis.
Loewenstein-Lichtenstein Y; Glick D; Gluzman N; Sternfeld M; Zakut H; Soreq H
Mol Pharmacol; 1996 Dec; 50(6):1423-31. PubMed ID: 8967962
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase.
Huang L; Luo Z; He F; Lu J; Li X
Bioorg Med Chem; 2010 Jun; 18(12):4475-84. PubMed ID: 20471843
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors.
Huang L; Shi A; He F; Li X
Bioorg Med Chem; 2010 Feb; 18(3):1244-51. PubMed ID: 20056426
[TBL] [Abstract][Full Text] [Related]
20. Probing the mid-gorge of cholinesterases with spacer-modified bivalent quinazolinimines leads to highly potent and selective butyrylcholinesterase inhibitors.
Chen X; Tikhonova IG; Decker M
Bioorg Med Chem; 2011 Feb; 19(3):1222-35. PubMed ID: 21232964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
